Ceramide synthesis inhibitors prevent lipid-induced insulin resistance through the DAG-PKCε-insulin receptorT1150 phosphorylation pathway
Cell Reports · 2024
DOI: 10.1016/j.celrep.2024.114746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Weiwei Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA; Department of Endocrinology, The First Affiliated Hospital of Zhe…. Hauptthemen laut MEDLINE: Insulin Resistance, Protein Kinase C-epsilon, Ceramides, Diglycerides. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, U.S. Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA; Department of Endocrinology, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang 310003, China.
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA.
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA; Department of Endocrinology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, China.
- Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA; VA Connecticut Healthcare System, West Haven, CT 06516, USA. Electronic address: varman.samuel@yale.edu.
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA; Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06510, USA; Howard Hughes Medical Institute, Ch…
Förderung
- National Institutes of Health
- U.S. Department of Health and Human Services
- National Institute of Diabetes and Digestive and Kidney Diseases
- Yale School of Medicine
Zitieren
APA
Xu, W., Zhang, D., Ma, Y., Gaspar, R. C., Kahn, M., Nasiri, A., Murray, S., Samuel, V. T., & Shulman, G. I. (2024). Ceramide synthesis inhibitors prevent lipid-induced insulin resistance through the DAG-PKCε-insulin receptorT1150 phosphorylation pathway. Cell Reports. https://doi.org/10.1016/j.celrep.2024.114746
Vancouver
Xu W, Zhang D, Ma Y, Gaspar RC, Kahn M, Nasiri A, et al. Ceramide synthesis inhibitors prevent lipid-induced insulin resistance through the DAG-PKCε-insulin receptorT1150 phosphorylation pathway. Cell Reports. 2024. doi:10.1016/j.celrep.2024.114746
BibTeX
@article{Xu2024,
author = {Xu, Weiwei and Zhang, Dongyan and Ma, Yumin and Gaspar, Rafael C and Kahn, Mario and Nasiri, Ali and Murray, Sue and Samuel, Varman T and Shulman, Gerald I},
title = {Ceramide synthesis inhibitors prevent lipid-induced insulin resistance through the DAG-PKCε-insulin receptorT1150 phosphorylation pathway},
journal = {Cell Reports},
year = {2024},
doi = {10.1016/j.celrep.2024.114746}
}
EUVIMED